Apr 11, 2022
AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

Mar 31, 2022
AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 28, 2022
AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress

Mar 24, 2022
AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting

Mar 23, 2022
AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Mar 16, 2022
AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

Mar 09, 2022
AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting

Mar 09, 2022
AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting

Mar 08, 2022
AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer

Mar 07, 2022
AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline

 6   7   8   9   10     11    12   13   14   15   16